Meeting
2023 ASCO Annual Meeting
Three-dimensional telomere profiling to predict risk of progression in smoldering multiple myeloma.
Authors
Shaji Kumar
Division of Hematology, Mayo Clinic, Rochester, MN
Shaji Kumar , S. Vincent Rajkumar , Dragan Jevremovic , Robert A. Kyle , Sabine Mai , Sherif Louis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8056)
DOI
10.1200/JCO.2023.41.16_suppl.8056
Abstract #
8056
Poster Bd #
48
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Differentiating asymptomatic monoclonal gammopathy (AMG including MGUS and AMM) from clinical multiple myeloma (CMM) by gene expression profiling of purified plasma cells (PC-GEP).
First Author: Rashid Khan
Poster
2024 ASCO Annual Meeting
From criteria to clinic: How updated SLiM CRAB criteria influence multiple myeloma diagnostic activity.
First Author: Mengmeng Ji
Poster
2024 ASCO Annual Meeting
Unveiling consistency: A large-scale analysis of conference proceedings and subsequent publications in oncology clinical trials using large language models.
First Author: Kyeryoung Lee
Poster
2024 ASCO Annual Meeting
Implementation and preliminary efficacy of a risk stratification system +/- patient-reported outcomes monitoring for patients with hospital-diagnosed advanced lung cancer.
First Author: Emily Miller Ray